Trial NCT04341389
Publication Zhu F, Lancet, 2020
Primary outcome on the report: Incidence of adverse reactions within 14 days after the injection. Geometric mean titres (GMTs) of RBD-specific ELISA antibody responses and neutralising antibody responses against live virus or pseudovirus at day 28 post vaccination.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.